O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-3.5%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$4.82B
AUM Growth
+$4.82B
(-12%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-3.65%
Top 10 Holdings %
Top 10 Hldgs %
44.7%
Holding
132
New
19
Increased
23
Reduced
22
Closed
17
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$93.6M |
| 2 |
Neurocrine Biosciences
NBIX
|
$86.8M |
| 3 |
Edwards Lifesciences
EW
|
$84.8M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$38.9M |
| 5 |
Cytokinetics
CYTK
|
$38.4M |
Top Sells
| 1 |
Amgen
AMGN
|
$81.3M |
| 2 |
Elevance Health
ELV
|
$55.2M |
| 3 |
Merck
MRK
|
$48.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$47.5M |
| 5 |
Evolent Health
EVH
|
$47.1M |
Sector Composition
| 1 | Healthcare | 98.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$1.51B
| $401M | 8.25% | 15,021,721 | – | – |
|
|
SVA
2
DELISTED
Sinovac Biotech, Ltd
SVA
| $334M | 6.87% | 2,718,735 | – | – |
|
3
Boston Scientific
BSX
$156B
| $282M | 5.81% | 3,160,300 -112,700 | -3% | -$10.1M |
|
4
Eli Lilly
LLY
$657B
| $261M | 5.36% | 337,600 | – | – |
|
5
Intuitive Surgical
ISRG
$170B
| $210M | 4.31% | 401,700 -32,100 | -7% | -$16.8M |
|
6
Enliven Therapeutics
ELVN
$1.2B
| $179M | 3.68% | 7,959,538 | – | – |
|
|
7
Neurocrine Biosciences
NBIX
$13.8B
| $128M | 2.63% | 938,120 +635,900 | +210% | +$86.8M |
|
8
Stryker
SYK
$150B
| $124M | 2.55% | 344,400 | – | – |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $117M | 2.41% | 963,400 +8,900 | +0.9% | +$1.08M |
|
10
argenx
ARGX
$43.6B
| $117M | 2.4% | 189,700 -14,800 | -7% | -$9.1M |
|
11
Disc Medicine
IRON
$2.07B
| $113M | 2.33% | 1,785,571 | – | – |
|
12
Tenet Healthcare
THC
$16.3B
| $100M | 2.06% | 792,000 +10,000 | +1% | +$1.26M |
|
13
Ionis Pharmaceuticals
IONS
$6.79B
| $98.5M | 2.03% | 2,817,347 +492,900 | +21% | +$17.2M |
|
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $97.8M | 2.01% | 415,600 +165,300 | +66% | +$38.9M |
|
|
UPB
15
Upstream Bio, Inc. Common Stock
UPB
$923M
| $93.6M | 1.93% | +5,693,589 | New | +$93.6M |
|
16
ARS Pharmaceuticals
SPRY
$1.15B
| $87.4M | 1.8% | 8,288,510 | – | – |
|
|
17
Edwards Lifesciences
EW
$47.8B
| $84.8M | 1.74% | +1,145,302 | New | +$84.8M |
|
|
18
Merck
MRK
$210B
| $82.6M | 1.7% | 829,900 -486,100 | -37% | -$48.4M |
|
19
ArriVent BioPharma
AVBP
$776M
| $80.6M | 1.66% | 3,027,328 | – | – |
|
20
Biogen
BIIB
$19.4B
| $77.9M | 1.6% | 509,100 -303,900 | -37% | -$46.5M |
|
21
Integer Holdings
ITGR
$3.78B
| $76.2M | 1.57% | 575,000 | – | – |
|
|
22
Cytokinetics
CYTK
$4.23B
| $74.5M | 1.53% | 1,584,005 +817,099 | +107% | +$38.4M |
|
|
MBX
23
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $70.3M | 1.45% | 3,812,215 | – | – |
|
24
UnitedHealth
UNH
$281B
| $66.2M | 1.36% | 130,900 -48,100 | -27% | -$24.3M |
|
25
Natera
NTRA
$23.1B
| $65.4M | 1.34% | 413,000 -274,500 | -40% | -$43.5M |
|